Elraglusib

Elraglusib in combination with GnP showed significant improvements in 1-year survival rate (43.6% vs 22.5%) and median overall survival (9.3 months vs 7.2 months) in metastatic pancreatic ductal adenocarcinoma patients, with a 37% reduction in risk of death and increased Objective Response Rates and Disease Control Rates. The trial continues with topline data anticipated in 1H 2025.

Actuate Therapeutics' elraglusib reduced death risk by 37% in a Phase I/II metastatic pancreatic cancer trial, doubling one-year survival rate to 43.6% with elraglusib-GnP vs 22.5% with GnP alone. The company plans a Phase III study.

Actuate Therapeutics reports elraglusib combined with GnP significantly improves survival in pancreatic cancer patients, showing a 43.6% 1-year survival rate vs 22.5% for GnP alone, with a 37% death risk reduction. The therapy also increased median overall survival by nearly two months, demonstrating a favorable risk-benefit profile. Plans to discuss findings with FDA in 1H 2025.

Actuate Therapeutics announced Phase 2 trial results for elraglusib combined with chemotherapy, showing improved survival rates in metastatic pancreatic cancer. The combination doubled one-year survival to 43.6% and increased median overall survival by two months. Actuate plans FDA discussions in 2025 for a Phase 3 trial. The company also received FDA rare pediatric disease designation for elraglusib in Ewing sarcoma treatment.

Actuate Therapeutics (ACTU) reported positive Phase 2 trial results for elraglusib combined with gemcitabine/nab-paclitaxel in treating metastatic pancreatic ductal adenocarcinoma, showing significant survival benefits over GnP alone, including higher 1-year survival rates and median overall survival.

Interim data shows elraglusib-GnP combination significantly improves survival rates in pancreatic cancer patients, with a 1-year survival rate of 43.6% vs 22.5% in the control arm. The combination also demonstrated a 37% reduction in death risk and increased median overall survival. Safety profile was favorable, with similar adverse events between arms. Two patients saw significant tumor reduction, enabling surgery. The study supports elraglusib's potential as a treatment for metastatic pancreatic cancer.

Elraglusib combined with GnP showed significant improvements in 1-year survival rate (43.6% vs 22.5%) and median overall survival (9.3 vs 7.2 months) in mPDAC patients. The combination also increased ORR and DCR, with a favorable risk-benefit profile. Topline data expected in 1H 2025.